Share on StockTwits

Investment analysts at ING Group raised their price objective on shares of Evoke Pharma (NASDAQ:EVOK) from $19.00 to $20.00 in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. ING Group’s price target would suggest a potential upside of 172.11% from the company’s current price.

Shares of Evoke Pharma (NASDAQ:EVOK) traded up 0.82% during mid-day trading on Tuesday, hitting $7.4101. 1,737 shares of the company’s stock traded hands. Evoke Pharma has a one year low of $6.48 and a one year high of $14.25. The stock has a 50-day moving average of $8.04 and a 200-day moving average of $9.02. The company’s market cap is $44.5 million.

Evoke Pharma (NASDAQ:EVOK) last released its earnings data on Tuesday, May 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.13. Analysts expect that Evoke Pharma will post $-2.55 EPS for the current fiscal year.

A number of other firms have also recently commented on EVOK. Analysts at Cantor Fitzgerald reiterated a “buy” rating on shares of Evoke Pharma in a research note on Tuesday. They now have a $20.00 price target on the stock, up previously from $19.00. Separately, analysts at Feltl & Co. initiated coverage on shares of Evoke Pharma in a research note on Tuesday, April 22nd. They set a “strong-buy” rating on the stock. Finally, analysts at Laidlaw initiated coverage on shares of Evoke Pharma in a research note on Tuesday, April 22nd. They set a “buy” rating and a $19.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $27.40.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (NASDAQ:EVOK), disorders and diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.